Pharmacokinetics of selective estrogen receptor modulators.
about
Selective estrogen receptor modulators for preventing and treating postmenopausal osteoporosisFDA-approved selective estrogen receptor modulators inhibit Ebola virus infection.Venous thromboembolic diseaseSelective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifeneLasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophyLasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosisOptimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of Salmon CalcitoninCharacterization of raloxifene glucuronidation: potential role of UGT1A8 genotype on raloxifene metabolism in vivo.Controlled release of raloxifene by nanoencapsulation: effect on in vitro antiproliferative activity of human breast cancer cells.Lasofoxifene: Evidence of its therapeutic value in osteoporosis.The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancerAdenylate kinase release as a high-throughput-screening-compatible reporter of bacterial lysis for identification of antibacterial agents.Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy.Clinical pharmacology of multiple doses of lasofoxifene in postmenopausal women.Oral administration of the broad-spectrum antibiofilm compound toremifene inhibits Candida albicans and Staphylococcus aureus biofilm formation in vivo.Ospemifene use in postmenopausal women.Benzothiophene Selective Estrogen Receptor Modulators Provide Neuroprotection by a novel GPR30-dependent MechanismEstrogen receptor antagonists are anti-cryptococcal agents that directly bind EF hand proteins and synergize with fluconazole in vivo.Structure-activity relationships for the antifungal activity of selective estrogen receptor antagonists related to tamoxifenRaloxifene pharmacokinetics in males with normal and impaired renal function.Therapeutic concentrations of raloxifene augment nitric oxide-dependent coronary artery dilatation in vitroThe Dual Estrogen Receptor α Inhibitory Effects of the Tissue-Selective Estrogen Complex for Endometrial and Breast Safety.The road map to oral bioavailability: an industrial perspective.Bazedoxifene: a third-generation selective estrogen receptor modulator for treatment of postmenopausal osteoporosis.Effects of ospemifene on drug metabolism mediated by cytochrome P450 enzymes in humans in vitro and in vivo.Clinically used selective estrogen receptor modulators affect different steps of macrophage-specific reverse cholesterol transport.Antifungal activity of tamoxifen: in vitro and in vivo activities and mechanistic characterizationBazedoxifene: a selective estrogen-receptor modulator.Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis.Measuring selective estrogen receptor modulator (SERM)-membrane interactions with second harmonic generationLasofoxifene: selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.Profile of ospemifene in the breast.Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer.Folate-targeted nanoparticles based on albumin and albumin/alginate mixtures as controlled release systems of tamoxifen: synthesis and in vitro characterization.Tamoxifen-loaded thiolated alginate-albumin nanoparticles as antitumoral drug delivery systems.Lasofoxifene, from the preclinical drug discovery to the treatment of postmenopausal osteoporosis.Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms.Raloxifene relaxes rat intrarenal arteries by inhibiting Ca2+ influx.Raloxifene glucuronidation in liver and intestinal microsomes of humans and monkeys: contribution of UGT1A1, UGT1A8 and UGT1A9.Hemodynamic effects of acute and repeated exposure to raloxifene in ovariectomized sheep.
P2860
Q24200755-758D35F2-D880-42CC-B359-15FA5AFB16AFQ24568225-E54FDFD5-6029-4322-9AE7-7EB097495A22Q24631121-BC6CE67F-823E-480C-BC2D-C7A4A5D4A7AAQ24652524-68A62A4B-6514-4F2A-9CC9-DD39053D8A88Q28253298-78FAE75E-D3EE-4077-AACF-BE252E5C842EQ28258418-C49D94BE-4FA1-4A96-94E0-B28BA49C0F98Q33368276-C8B143C2-A6C7-4940-B4D2-B4A21E5BF72AQ33753957-39C00CF2-6EC0-4B44-BB4A-4117C593B1F0Q33800662-B24F60CC-4228-43B4-A156-AC9D4F93040AQ33973891-6FBAFE13-D2E6-493F-A83C-4471D865F8AEQ34253646-9153879C-A4C0-48E2-9A59-AC3D0380139BQ34425938-4697F8EF-2C77-416F-99DA-1DEFF297A931Q34497901-1CAE037F-FA17-4E77-96CE-023EBAB6ED8BQ34563953-1F1855CF-88DA-4079-9D43-E17B569BA105Q34597915-B4450A34-A3CF-4447-A0E5-A1764FCFBB35Q34982860-35F28032-AFBA-456D-9566-85DCCF227968Q35072737-6F4E7142-1CDC-4C2D-A1A8-EBDC051F4685Q35092521-5358A66D-0E5F-49FD-A071-BC07985D8003Q35643319-AE1D5040-A10C-4CB6-98B9-72BB075424A4Q35826870-8475CE4B-BCFC-4647-A233-22C010D98480Q35995207-19285DFC-7949-464C-BBF8-C3720926D87FQ36432425-54F07404-9B52-4672-9668-E3B9D6509DB6Q36543116-65F3FAD1-D04E-4373-B1D4-1730B81AD108Q36787639-EFD57120-FFB1-41CC-832F-55D18A7C22E8Q37091899-6AAA87F7-41C5-4BF0-ABCA-0A54F2DAF9CFQ37236276-CFAE56D1-5D67-4E16-B626-2780EDC135CBQ37274621-F60981F8-04EE-4277-9CB0-A075D98A119FQ37346144-66D5F9A3-37AA-4D4A-89F4-13FC817FD86FQ37412956-90858C9D-C8F0-4A42-ADD8-436D903B4EBEQ37731586-12886738-C743-4C28-85F9-ED2FEAFF6787Q37861982-1D67E5CD-3898-4486-B2B2-58986E10E457Q38129004-33EC8F9D-5B02-46F9-B848-539D4229B90FQ38719706-5D126E44-3923-4DD5-BF49-244934F5A9AAQ39114415-291381F8-7AC6-4757-B371-F49618C3C28AQ39384237-CFF5DA4C-41BE-46A0-945F-4F872A4ADE35Q39788803-397A7403-C3C7-4F55-9387-5993B10035CDQ43552073-C4D4031B-2F7E-43F5-A68E-E56C3741296EQ45267520-0DBA8742-521D-414B-A5C2-F83767B03911Q46689359-8090DECB-1C0C-45B8-A37E-E4D9AF788909Q46976029-0361DD38-5245-49BF-A7C6-01CF00F47E22
P2860
Pharmacokinetics of selective estrogen receptor modulators.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Pharmacokinetics of selective estrogen receptor modulators.
@ast
Pharmacokinetics of selective estrogen receptor modulators.
@en
Pharmacokinetics of selective estrogen receptor modulators.
@nl
type
label
Pharmacokinetics of selective estrogen receptor modulators.
@ast
Pharmacokinetics of selective estrogen receptor modulators.
@en
Pharmacokinetics of selective estrogen receptor modulators.
@nl
prefLabel
Pharmacokinetics of selective estrogen receptor modulators.
@ast
Pharmacokinetics of selective estrogen receptor modulators.
@en
Pharmacokinetics of selective estrogen receptor modulators.
@nl
P2093
P1476
Pharmacokinetics of selective estrogen receptor modulators.
@en
P2093
Gregory T Wurz
Karla C Morello
Michael W DeGregorio
P304
P356
10.2165/00003088-200342040-00004
P577
2003-01-01T00:00:00Z
P6179
1052002165